Rate My Professor Kentaro Takayama

Takayama’s research specializes in pharmaceutical chemistry and drug development, with key interests in peptide-based therapeutics, neuromedin U receptor modulators, myostatin inhibitors, inflammation, stress responses, taste sensitivity alterations, and crush syndrome mechanisms. The laboratory explores the gut-brain axis in psychiatric disorders like depression, taste disorders from anti-cancer drugs and diabetes, and peptide drugs for intractable diseases. Notable publications include “Discovery of a Pentapeptide Antagonist to Human Neuromedin U Receptor 1” (ACS Medicinal Chemistry Letters, 2024), “Suppressive Effects of Neuromedin U Receptor 2-Selective Peptide Agonists on Appetite and Prolactin Secretion in Mice” (ACS Medicinal Chemistry Letters, 2024), “Multiple site inflammation and acute kidney injury in crush syndrome” (Frontiers in Pharmacology, 2024), and “Doxorubicin-induced sweet taste sensitivity reduction and compensatory receptor expression in mice” (Chemical Senses, 2025). He has earned prestigious awards such as the Encouragement Award from The Pharmaceutical Society of Japan (2021), the Mizushima Shoji Memorial Research Award (2019), and the Japanese Peptide Society Encouragement Award (2018). Takayama holds leadership roles including Director of The Japanese Peptide Society since 2024, member of the Kyoto Health Longevity and Predisease Improvement Promotion Conference since 2022, and Representative of The Pharmaceutical Society of Japan from 2023 to 2025.